This topic contains a solution. Click here to go to the answer

Author Question: Which leadership scholar developed the main framework of adaptive leadership? a. House b. Bass ... (Read 72 times)

saliriagwu

  • Hero Member
  • *****
  • Posts: 537
Which leadership scholar developed the main framework of adaptive leadership?
 
  a. House
  b. Bass
  c. Kouzes
  d. Heifetz

Question 2

The contingent reward factor
 
  a. Is a reciprocal process of mutual influence
  b. Is a reciprocal process between two followers
  c. Is a process where follower effort is exchanged for specified rewards
  d. Is a negotiated process with equal rewards for follower and leader



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

krakiolit

  • Sr. Member
  • ****
  • Posts: 318
Answer to Question 1

D

Answer to Question 2

C




saliriagwu

  • Member
  • Posts: 537
Reply 2 on: Jul 8, 2018
Excellent


tranoy

  • Member
  • Posts: 344
Reply 3 on: Yesterday
Great answer, keep it coming :)

 

Did you know?

Earwax has antimicrobial properties that reduce the viability of bacteria and fungus in the human ear.

Did you know?

Side effects from substance abuse include nausea, dehydration, reduced productivitiy, and dependence. Though these effects usually worsen over time, the constant need for the substance often overcomes rational thinking.

Did you know?

Asthma-like symptoms were first recorded about 3,500 years ago in Egypt. The first manuscript specifically written about asthma was in the year 1190, describing a condition characterized by sudden breathlessness. The treatments listed in this manuscript include chicken soup, herbs, and sexual abstinence.

Did you know?

In 2006, a generic antinausea drug named ondansetron was approved. It is used to stop nausea and vomiting associated with surgery, chemotherapy, and radiation therapy.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library